

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
UNDER 37 C.F.R. § 1.10

"Express Mail" mailing label number: EL366966260US

Date of Mailing: October 1, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service, utilizing the "Express Mail Post Office to Addressee" service addressed to **Assistant Commissioner for Patents, Washington, DC 20231** and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.

Tracy L. Morton (Signature)

Signature Date: October 1, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application	)	<u>PATENT APPLICATION</u>
	)	
Inventor(s):	)	
Angelica Williams	)	
Carla Heise	)	
Meisa Propst	)	
Adam Sampson-Johannes	)	
Terry Hermiston	)	
David Kirn	)	
	)	
SC/Serial No.:	)	
Unknown	)	
	)	
Filed:	)	
Herewith	)	
	)	
Title:	)	
A Single Agent Method for Killing	)	
Tumor Associated Endothelial Cells	)	
Using Adenoviral Mutants	)	
	)	

APPLICATION TRANSMITTAL LETTER

Box PATENT APPLICATION  
Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants through their undersigned Attorney petitions the Commissioner to convert the above-identified Provisional Patent Application claiming priority under C.F.R. §1.53(b)(2) to an Ordinary Patent Application under C.F.R. §1.53.

Transmitted herewith for filing is the patent application identified as follows:

Inventor(s): Angelica Williams; Carla Heise; Meisa Propst; Adam Sampson-Johannes; Terry Hermiston; and David Kirn

Title: A Single Agent Method for Killing Tumor and Tumor Associated Endothelial Cells Using Adenoviral Mutants

No. of pages in Specification: 24; No. of Claims: 28.

No. of Sheets of Drawings: 7; Formal:[X]; Informal:[].

Preliminary Amendment

In the Specification

Page 1, line 11, before "Field of the Invention" add a new paragraph -- This invention claims priority from U.S. Provisional Application No. 60/105,701, Filed October 26, 1998 and U.S. Provisional Application No. 60/121,300, Filed February 23, 1999.--

The filing fee pursuant to 37 C.F.R. § 1.16 is determined as follows:

No. Filed	No. Extra	Rate Small Entity/ Large Entity		
Basic Fee		\$380.00 760.00	=	\$380.00
Total Claims <u>28</u>	- 20 = <u>8</u> *	X \$ 9.00 18.00	=	\$ <u>64.00</u>
Independent Claims <u>6</u>	- 3 = <u>3</u> *	X \$ 39.00 78.00	=	\$ <u>117.00</u>
First Presentation of Multiple Dependent Claim(s) <u>0</u>		\$130.00 260.00	=	\$ <u>          </u>
Total:			=	\$ <u>561.00</u>

\*If the difference is less than zero, enter "0".

[X] Please charge Deposit Account No. 15-0615 in the amount of \$561.00. A duplicate copy of this authorization is enclosed.

[X] The Commissioner is hereby authorized to charge underpayment of any fees (including those listed below) or credit any overpayment associated with this communication to Deposit Account No. 15-0615. A duplicate copy of this authorization is enclosed.

[X] Any additional filing fees under 37 C.F.R. § 1.16.

[X] Any patent application processing fees under 37 C.F.R. § 1.17.

This application is filed pursuant to 37 C.F.R. § 1.53 in the name of the above-identified Inventor(s).

Please direct all correspondence concerning the above-identified application to the following address:

Gregory Giotta, Ph.D.  
Vice President and Chief Legal Counsel  
ONYX Pharmaceuticals, Inc.  
3031 Research Drive  
Richmond, California 94806  
Telephone: (510) 262-8710

Respectfully submitted,

Date: October 1, 1999

By: 

Gregory Giotta  
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.  
3031 Research Drive  
Richmond, California 94806  
Telephone (510) 222-9700